AKT1 and neoplasm: Plasma protein levels of VEGF and EGF, gene mutations of KRAS, BRAF and PIK3CA, and expression of P27, phosphorylated EGFR and AKT in tumor tissues were also investigated for their potential roles as biomarkers of clinical outcomes.